Friedland I - Search Results

1

In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.

Friedland I, Mixson LA, Majumdar A, Motyl M, Woods GL. Friedland I, et al. J Chemother. 2002 Oct;14(5):483-91. doi: 10.1179/joc.2002.14.5.483. J Chemother. 2002. PMID: 12462428

2

Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.

Pelak BA, Woods GL, Teppler H, Friedland I, Bartizal K, Motyl M. Pelak BA, et al. Among authors: friedland i. J Chemother. 2002 Jun;14(3):227-33. doi: 10.1179/joc.2002.14.3.227. J Chemother. 2002. PMID: 12120874

3

Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.

Friedland I, Gallagher G, King T, Woods GL. Friedland I, et al. J Chemother. 2004 Oct;16(5):437-41. doi: 10.1179/joc.2004.16.5.437. J Chemother. 2004. PMID: 15565908

4

Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.

Friedland IR, Isaacs R, Mixson LA, Motyl M, Woods GL. Friedland IR, et al. Diagn Microbiol Infect Dis. 2002 May;43(1):61-4. doi: 10.1016/s0732-8893(02)00380-2. Diagn Microbiol Infect Dis. 2002. PMID: 12052630

5

Ertapenem therapy for community-acquired pneumonia in the elderly.

Woods GL, Isaacs RD, McCarroll KA, Friedland IR. Woods GL, et al. J Am Geriatr Soc. 2003 Nov;51(11):1526-32. doi: 10.1046/j.1532-5415.2003.51507.x. J Am Geriatr Soc. 2003. PMID: 14687380 Clinical Trial.

6

Safety and tolerability of ertapenem.

Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R. Teppler H, et al. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii75-81. doi: 10.1093/jac/dkh209. J Antimicrob Chemother. 2004. PMID: 15150186 Review.

7

Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.

Friedland IR, McCarroll KA, DiNubile MJ, Woods GL. Friedland IR, et al. Pulm Pharmacol Ther. 2004;17(4):199-203. doi: 10.1016/j.pupt.2004.03.002. Pulm Pharmacol Ther. 2004. PMID: 15219264

8

Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.

Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, Weinstein RA, Quinn JP. Dinubile MJ, et al. Among authors: friedland i. Eur J Clin Microbiol Infect Dis. 2005 Jul;24(7):443-9. doi: 10.1007/s10096-005-1356-0. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15990986 Clinical Trial.

9

Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000.

Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Friedland I, et al. Infect Control Hosp Epidemiol. 2003 Aug;24(8):607-12. doi: 10.1086/502252. Infect Control Hosp Epidemiol. 2003. PMID: 12940583

10

Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000.

Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Friedland I, et al. Diagn Microbiol Infect Dis. 2003 Apr;45(4):245-50. doi: 10.1016/s0732-8893(02)00503-5. Diagn Microbiol Infect Dis. 2003. PMID: 12729994

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters